Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman Sells 23,023 Shares

Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 23,023 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $1.55, for a total value of $35,685.65. Following the completion of the transaction, the chief executive officer now owns 3,230,000 shares of the company’s stock, valued at $5,006,500. This trade represents a 0.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Cerus Trading Up 1.9 %

CERS stock opened at $1.61 on Thursday. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19. Cerus Co. has a 12-month low of $1.38 and a 12-month high of $2.59. The stock has a market cap of $299.12 million, a price-to-earnings ratio of -14.64 and a beta of 1.29. The business’s 50-day moving average is $1.74 and its 200 day moving average is $1.80.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The company had revenue of $50.81 million for the quarter, compared to analysts’ expectations of $50.81 million. On average, sell-side analysts anticipate that Cerus Co. will post -0.08 EPS for the current fiscal year.

Institutional Trading of Cerus

Several institutional investors have recently made changes to their positions in the company. Rockport Wealth LLC purchased a new stake in shares of Cerus during the fourth quarter worth $25,000. Cibc World Markets Corp acquired a new stake in Cerus during the fourth quarter worth approximately $26,000. R Squared Ltd acquired a new position in shares of Cerus in the 4th quarter valued at $29,000. Virtu Financial LLC purchased a new stake in Cerus during the 4th quarter worth $33,000. Finally, Dark Forest Capital Management LP acquired a new position in Cerus during the 4th quarter worth $34,000. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $4.00 target price on shares of Cerus in a research report on Friday, February 21st.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.